Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?
Amneal Pharmaceuticals (AMRX) recently received a positive EU opinion for Hopledo, a Parkinson's disease therapy, contributing to its strong share price performance. While a discounted cash flow model suggests it's undervalued with a fair value of $17.25, its P/E ratio of 44.8x indicates it's expensive compared to industry averages and peers. Investors are advised to consider both the underlying data and potential risks like generics pricing pressure and biosimilar execution before making investment decisions.
Price to sales forward of Amneal Pharmaceuticals, Inc. Class A – SWB:2DT
This article provides the "Price to sales forward" value for Amneal Pharmaceuticals, Inc. Class A (SWB:2DT) on the Stuttgart Stock Exchange. It notes that the market is currently closed with no trades. The content primarily focuses on financial data for this specific company.
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The FDA announced that Eli Lilly, Regeneron, and five other companies have been selected for its PreCheck Pilot Program. This initiative aims to bolster domestic pharmaceutical manufacturing and improve the resilience of the U.S. drug supply chain by providing early regulatory engagement for new U.S. production facilities. The program is part of a broader effort to provide a predictable regulatory pathway for companies wishing to manufacture medicines in the U.S. and ensure access to critical therapies, reflecting the administration's goal to rebuild pharmaceutical manufacturing.
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX)
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is seeking stockholder approval to acquire 100% of Kashiv BioSciences’ membership interests for $375 million in cash and 28,942,108 shares of Amneal Class A common stock. Sellers are also eligible for up to $350 million in contingent cash payments tied to U.S. regulatory milestones and 25% of annual aggregate gross profits above specified hurdles for up to 12 years. The transaction, unanimously recommended by Amneal's Independent Committee and Board, is subject to stockholder approvals and regulatory clearances, with a special meeting scheduled for July 31, 2026.
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June
This article announces the filing of Form DEF 14A by Amneal Pharmaceuticals Inc Class A for June 26. It notes that the form was updated on June 26, 2026. The piece also includes standard disclaimers about the risks inherent in financial and cryptocurrency trading.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. (ticker 2DT on the Munich Stock Exchange), including analyst price targets, revenue and earnings estimates, and historical price data. It details the company's financial performance, such as recent earnings per share and revenue figures, net income, EBITDA, and employee count. The article also addresses frequently asked questions about buying 2DT stocks and its dividend policy.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. Class A (2DT) stock, including price targets from analysts ranging between 13.82 EUR and 16.41 EUR. It also details the company's past financial performance, upcoming earnings report, and other key financial metrics like revenue, net income, and EBITDA. Additionally, it addresses common questions about the stock, such as its ticker, historical high/low prices, and dividend policy.
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX)
This article provides an overview of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and details on recent earnings and revenue. The article also addresses frequently asked questions about the company's financials and future outlook, recommending comprehensive research before investing.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. Class A (ticker 2DT on Tradegate Exchange), including analyst price targets, historical stock data, and expected financial performance. Analysts have a maximum price estimate of 16.41 EUR and a minimum estimate of 13.82 EUR, with the company's next earnings report scheduled for August 12, 2026. The report also details past earnings, revenue, net income, and provides answers to frequently asked questions about the stock.
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com
Amneal Pharmaceuticals (AMRX) stock has reached a new 52-week high of $16.62, marking a 103.14% increase over the past year. This milestone follows impressive Q1 2026 financial results, including an EPS of $0.27 and revenue of $723 million, and recent FDA approval for its romidepsin injection solution. The company also announced positive interim data from its Phase 4 ELEVATE-PD study for CREXONT, a Parkinson’s disease treatment.
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD
Amneal Pharmaceuticals stock reached a 52-week high of $16.62, currently trading at $16.64 with a $5.31 billion market capitalization, reflecting a 103.14% increase over the past year. This surge is fueled by strong investor confidence, impressive Q1 2026 financial results, and positive developments like FDA approval for romidepsin and promising interim data from the CREXONT Phase 4 study for Parkinson’s disease. Despite trading above its Fair Value, the company maintains a "GREAT" Financial Health score on InvestingPro, highlighting its resilience and growth potential.
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Amneal Pharmaceuticals (AMRX) has experienced a significant rally, with its stock price closing at US$16.21. Despite this, an independent intrinsic value estimate suggests the stock is currently undervalued by about 6%, with a consensus analyst price target of $17.25. However, while the narrative points to undervaluation based on growth and profitability assumptions, the company faces pressures from a competitive generics market and substantial debt, and its P/E ratio appears high compared to peers, creating mixed signals for investors.
Top 3 Health Care Stocks That May Collapse This Quarter
The article identifies three healthcare stocks—Cardinal Health, TG Therapeutics, and Amneal Pharmaceuticals—that may be overbought according to the Relative Strength Index (RSI) as of June 15, 2026. Despite recent positive news and stock gains for all three companies, their high RSI values (above 70) suggest they could be due for a correction. The article emphasizes the RSI as a key momentum indicator for short-term trading decisions.
Amneal Pharmaceuticals (AMRX) Is Up 19.0% After CREXONT Data And New CGT Oncology Approval - What's Changed
Amneal Pharmaceuticals (AMRX) recently saw a 19.0% stock increase following positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and FDA approval for its romidepsin injection for cutaneous T-cell lymphoma. These developments reinforce the company's strategy to expand into branded and complex therapies, moving beyond its U.S. generics business. Investors are encouraged to assess how these advancements, alongside ongoing generic pricing pressures, will influence Amneal's long-term performance and market valuation.
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD
Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $15.44, experiencing an 88% increase over the past year. This surge is attributed to the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations, and key product developments like FDA approval for romidepsin injection and positive interim results for its Parkinson's drug CREXONT. InvestingPro rates the company's financial health as "GREAT."
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com
Amneal Pharmaceuticals Inc. Class A stock reached a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, reflecting an 88% increase over the past year. This surge is attributed to the company's strong financial health and recent positive developments, including exceeding Q1 2026 earnings and revenue expectations, FDA approval for its romidepsin injection, and positive interim results from its CREXONT Parkinson's drug study. InvestingPro analysis suggests the stock is trading near its Fair Value, and the company has a "GREAT" financial health score.
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, representing an 88% increase over the past year. This surge reflects strong investor confidence and the company's "GREAT" financial health score, according to InvestingPro. The company also reported strong Q1 2026 financial results, surpassing EPS and revenue expectations, and secured FDA approval for a new romidepsin injection solution, alongside positive interim results for its Parkinson's drug, CREXONT.
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com
Amneal Pharmaceuticals stock reached a new 52-week high of $15.44, representing an 88% increase over the past year. This surge is supported by the company's strong financial health, positive first-quarter 2026 results which exceeded expectations, and recent FDA approval for a romidepsin injection solution. Additionally, interim results for their Parkinson's drug CREXONT showed improved patient outcomes.
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope has launched its "Hope Alliance" campaign, aimed at expanding access to longer-dated medications for low-income and uninsured patients nationwide. Amneal Pharmaceuticals is the first manufacturer to commit significant support, ensuring a reliable supply of critical chronic care therapies. This initiative moves beyond traditional short-dated donations to create a sustainable supply chain for patients, exemplified by Valbai's story, who relies on consistent medication to manage severe chronic conditions.
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data
Amneal Pharmaceuticals (AMRX) recently received FDA approval for its romidepsin injection and positive interim Phase 4 data for Parkinson's treatment CREXONT, contributing to an 80.45% 1-year total shareholder return. Despite being valued at $13.75 against an estimated fair value of $17.20, suggesting undervaluation, the stock's P/E ratio of 35.9x is richer than peers, indicating less room for error if expectations are not met. The company's strategic partnerships and expansion into high-growth categories are projected to drive future revenue, but high debt levels and U.S. generics market pressure pose challenges.
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX)
Amneal Pharmaceuticals (AMRX) shares advanced after the company secured FDA clearance for its generic version of a cancer treatment. The approval is for a bendamustine hydrochloride injection, a chemotherapy drug used to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The product is expected to be available in 2mg/mL and 4mg/mL concentrations in the second half of 2026.
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com
Amneal Pharmaceuticals (NASDAQ:AMRX) shares rose after the FDA approved its romidepsin injection solution for cutaneous T-cell lymphoma, granting 180 days of market exclusivity. This ready-to-use formulation offers an alternative to a previously withdrawn product and generated approximately $78 million in U.S. sales for its lyophilized powder form in the past year. Amneal has a strong record of Competitive Generic Therapy approvals since 2018.
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com
Amneal Pharmaceuticals Inc. Class A shares rose in premarket trading following FDA approval for its romidepsin injection solution. The product, indicated for cutaneous T-cell lymphoma, received Competitive Generic Therapy designation, granting Amneal 180 days of market exclusivity. This ready-to-use formulation offers an alternative to a previously withdrawn lyophilized powder version, with U.S. annual sales for the lyophilized powder estimated at $78 million.
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX)
Amneal Pharmaceuticals has received FDA clearance for its Biologics License Application (BLA) for Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta. This approval marks Amneal's first biosimilar BLA approval, expanding its oncology portfolio. Fylnetra helps reduce the incidence of infection in cancer patients undergoing myelosuppressive chemotherapy.
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) saw its shares rise in premarket trading after receiving FDA approval for its romidepsin injection solution. This drug, a histone deacetylase inhibitor for cutaneous T-cell lymphoma, offers a ready-to-use alternative and is eligible for 180 days of market exclusivity under Competitive Generic Therapy designation. Amneal has received the most CGT approvals in the industry since 2018.
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug
Amneal Pharmaceuticals Inc. Class A shares rose in premarket trading after receiving FDA approval for its romidepsin injection solution. This solution, an alternative to a previously withdrawn formulation, is a histone deacetylase inhibitor for treating cutaneous T-cell lymphoma and has received Competitive Generic Therapy designation, granting Amneal 180 days of market exclusivity. Amneal noted that it has received the most CGT approvals in the industry since 2018.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains
Amneal Pharmaceuticals (AMRX) has seen recent gains and strong long-term returns, prompting an assessment of its valuation. Simply Wall St estimates a fair value of $17.00, suggesting the stock is currently undervalued at its trading price of $13.17. This bullish outlook is driven by potential earnings growth from strategic partnerships and expansion into new markets, although risks like generic price pressure and high debt could impact the fair value.
[144] Amneal Pharmaceuticals, Inc. SEC Filing
This article details an SEC Form 144 filing by Amneal Pharmaceuticals, Inc. (AMRX). The filing indicates a proposed sale of 34,819 shares of Class A Common Stock by an individual through Merrill Lynch on May 11, 2026, with an aggregate market value of 450,416. The shares were acquired on May 7, 2026, through equity compensation from the issuer.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness
Amneal Pharmaceuticals (AMRX) has experienced mixed share performance despite a strong one-year return, leading to a reassessment of its valuation. The company is considered 27.1% undervalued with a narrative fair value of $17.00, driven by strategic partnerships and expansion into high-growth categories. However, its current P/E ratio of 32.4x is higher than the industry average, which could indicate that optimism is already factored into the price.
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg
Amneal Pharmaceuticals director Deborah M. Autor sold 34,819 shares of Class A Common Stock on May 11, 2026, at a weighted average price of $12.94 per share. Following this open-market transaction, her direct holdings in the company amount to 93,660 shares. The sale, valued at approximately $450,558, occurred in multiple trades ranging from $12.75 to $13.27.
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares
Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake by converting 34,819 restricted stock units into Class A Common Stock on May 7, 2026. This transaction brought her direct holdings to 128,479 Class A shares. Additionally, she was granted 19,824 new restricted stock units on May 6, 2026.
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23%
Amneal Pharmaceuticals reported strong Q1 2026 financial results with net revenue reaching $723 million and GAAP net income of $62 million. The company saw a significant 23% rise in specialty drug sales, driven by key branded products, and affirmed its increased full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS. Despite generally positive fundamental news, historical market reactions to Amneal's earnings have shown mixed price movements.
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units
Amneal Pharmaceuticals director Jeffrey P. George recently engaged in equity compensation activities. He exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock, bringing his direct holdings to 344,614 shares. Additionally, on May 6, 2026, he was granted 19,824 new RSUs, which will vest according to the company’s standard schedule.
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality
Amneal Pharmaceuticals (AMRX) reported a profit rebound in FY 2025, with net income swinging to US$72.1 million, but the presence of a US$58.0 million one-off loss raises concerns about earnings quality. While a DCF fair value suggests the stock is undervalued, its high P/E ratio compared to peers and underlying financial risks like high debt and weak interest coverage create mixed opinions among investors. The article highlights that both bullish and bearish interpretations of AMRX's performance exist, urging investors to consider further analysis.
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant
Amneal Pharmaceuticals director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common shares at no cost, increasing his direct holdings to 75,077 shares. He also received a new grant of 19,824 RSUs on May 6, 2026. This activity is considered routine equity compensation and does not involve open-market stock purchases or sales.
Amneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals reported a strong start to 2026, with first-quarter net revenue of $723 million, GAAP net income of $62 million, and adjusted EBITDA of $202 million. The company affirmed its previously announced increased full-year 2026 guidance, citing strong performance in its Specialty business and growth in Affordable Medicines. Amneal's co-CEOs highlighted the diversified business and multiple growth drivers as key to its success.
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity
Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock at $0.00 per share, bringing his direct ownership to 1,643,963 shares. Additionally, on May 6, 2026, he was granted 19,824 restricted stock units that will vest according to the company's director vesting schedule.
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares
Amneal Pharmaceuticals director John Kiely exercised 34,819 restricted stock units (RSUs) on May 7, 2026, receiving an equal number of Class A Common Stock shares at $0.00 per share. He also received a new RSU grant of 19,824 units on May 6, 2026. Following these transactions, Kiely directly owns 260,252 Class A Common Stock shares.
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)
Amneal Pharmaceuticals director Ted C. Nark increased his equity stake by exercising 34,819 restricted stock units into Class A Common Stock shares on May 7, 2026. This transaction, part of a stock-based compensation, brought his direct holdings to 325,848 shares. Additionally, Nark received a new grant of 19,824 restricted stock units on May 6, 2026, with future vesting.
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant
Amneal Pharmaceuticals director Paul M. Meister recently exercised 48,747 Restricted Stock Units, converting them into Class A shares, increasing his direct holdings to 832,800 shares. Additionally, he was granted a new 30,837 Restricted Stock Unit award. These transactions, detailed in a Form 4 SEC filing, highlight recent equity compensation activities by a key insider at Amneal.
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant
Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake by exercising 34,819 restricted stock units (RSUs) into Class A Common Stock. He also received a new grant of 19,824 restricted stock units, further boosting his potential share ownership in the company. Following these transactions, Shlomo directly owns 320,804 shares of Amneal's Class A Common Stock.
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition
Amneal Pharmaceuticals reported a significant surge in Q1 2026 profit, with net income more than tripling to $78.0 million and diluted EPS at $0.19, driven by higher gross margins and strong Specialty segment performance. The company also announced a definitive agreement to acquire Kashiv BioSciences for $375 million in cash, 28.9 million Class A shares, and up to $350 million in contingent payments, alongside a deal with MSN Laboratories for mirabegron distribution. Despite improved earnings, Amneal remains highly leveraged with $2.69 billion in debt and faces ongoing legal and settlement obligations, including $79.3 million for opioid litigation.
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held
Amneal Pharmaceuticals reported strong first-quarter 2026 results, with net revenue increasing by 4% to $722.5 million and net income attributable to Amneal soaring to $62.3 million from $12.2 million a year earlier. The company saw significant margin expansion due to growth in its Specialty segment and strategic portfolio adjustments within Affordable Medicines and AvKARE. Amneal reaffirmed its full-year 2026 guidance, projecting net revenue between $3.05 billion and $3.15 billion and adjusted diluted EPS of $0.95 to $1.05, despite a negative operating cash flow in Q1.
Amneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong first-quarter 2026 financial results, with net revenue increasing by 4% to $723 million and GAAP net income soaring by 411% to $62 million. The company affirmed its raised full-year 2026 guidance, driven by robust performance in its Specialty and Affordable Medicines segments, and the strategic acquisition of Kashiv BioSciences.
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors
Amneal Pharmaceuticals (AMRX) reported positive interim Phase 4 ELEVATE-PD data for CREXONT, showing improved "Good On" time and reduced "Off" time for Parkinson’s patients. Despite this clinical success, the company reaffirmed its 2026 revenue outlook of US$3.05 billion to US$3.15 billion, indicating that while the data supports a shift towards higher-value specialty neurology, the immediate financial impact is limited and the company still faces pressure from generics pricing. Investors need to consider this balanced view of branded growth versus ongoing generics market challenges.
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A (AMRX) News, Articles, Events & Latest Updates
This article provides an overview of Amneal Pharmaceuticals Inc. (AMRX) news, financial data, and analyst sentiment. It highlights the stock's current performance, market capitalization, earnings, and recent news including FDA approvals, partnerships, and growth strategies in generics, biosimilars, and injectables, while also addressing potential challenges like generic erosion for Rytary.
Earnings Scheduled For May 1, 2026
This article lists numerous companies scheduled to report their quarterly earnings on May 1, 2026, both before and after the bell. It provides estimated earnings per share (EPS) and revenue figures for each company, offering a comprehensive preview for investors.
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?
Amneal Pharmaceuticals (AMRX) has seen a significant 65.4% surge in its stock price over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 73.8% at $12.80 per share, with an intrinsic value of $48.82. However, its current P/E ratio of 56.67x is above the industry average and a proprietary "Fair Ratio" of 30.42x, indicating it might be overvalued based on earnings multiples.
Earnings call transcript: Amneal Pharma Q1 2026 beats EPS forecast
Amneal Pharmaceuticals Inc. (AMRX) reported strong Q1 2026 results, surpassing EPS forecasts with an adjusted EPS of $0.27 and revenue of $723 million. The company announced the acquisition of Kashiv BioSciences to become a fully integrated global biosimilars leader, anticipating significant growth and market diversification through this strategic move. Amneal also raised its full-year 2026 guidance, projecting 7-8% growth in affordable medicines and an increased total gross margin.
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story
Amneal Pharmaceuticals is acquiring Kashiv BioSciences to accelerate its biosimilar pipeline and create a fully integrated global biosimilars platform. This acquisition is expected to reshape Amneal's business mix towards biologics, diversifying its revenue base with multiple annual biosimilar launches planned by 2030. Despite recent stock declines, the deal positions Amneal to potentially enhance its long-term earnings profile and achieve analyst targets, though integration and interest coverage remain key considerations for investors.
